x

Join Advarra

Learn more about our company team, careers, and values. Join Advarra’s Talented team to take on engaging work in a dynamic environment.

See Jobs

Central Oncology Review

Specialized Institutional Review Board (IRB) Services for an Evolving Regulatory Landscape

Aligned with the needs of the growing and increasingly complex field of oncology, Advarra’s Central Oncology Review (COR) provides the robust human subject protections review cancer research institutions expect.

Learn More About COR

IRB Experience in Oncology

  • Antibody-drug conjugates
  • Bladder/urinary tract cancer
  • Blood and lymph cancers
  • Breast cancer
  • Cancer diagnostics
  • Cervical cancer
  • Chemotherapy
  • Colon/colorectal cancer
  • Endometrial cancer
  • Gastric cancer
  • Gene therapy
  • Head and neck cancer
  • Immunotherapy (such as CAR-T cell therapy)
  • Liver cancer
  • Lung cancer
  • Ovarian cancer
  • Pancreatic cancer
  • Palliative care management
  • Precision medicine (such as basket, umbrella, and targeted therapy trials)
  • Prostate cancer
  • Radiotherapy
  • Renal cancer
  • Sarcoma
  • Skin cancer

Developed and Led By Key Experts in Oncology Research and Institutional Human Subject Protection Programs

Michele Russell-Einhorn, JD
Chief Compliance Officer and Institutional Official, Advarra

Judith Carrithers, JD, MPA
VP, IRB Review, Advarra

Planning for Gene Therapy Research? Plan for IBC Review

Advarra’s coordinated IRB and IBC reviews help streamline the startup process

COR FAQs

Can Advarra serve as the single IRB for federally funded research?

Yes, Advarra oversees many single site and multisite studies supported by the NIH, NCI, DoD, and other agencies.

Can Advarra serve as the single IRB for oncology network research?

Yes, Advarra has experience supporting therapeutically specialized research networks. For more information, see IRB Services for Institutions, Health Systems, and Research Consortia.

How do I defer IRB oversight to Advarra?

We’ll work with your organization to establish a deferral agreement. Then we will coordinate with institutional leadership to accommodate local requirements and train teams as needed. Contact our team to get started.

OnCore CTMS

Streamline your research operations with OnCore, the preferred enterprise research CTMS of NCI-designated cancer centers

Related Resources

 
Blog

Legislation to Advance Equality and Inclusion in Oncology Clinical Trials

March 17, 2021

According to the Association for Clinical Oncology, individuals who identify as African American or Black make up 13.4% of the...

The Clinical Treatment Act and Henrietta Lacks Enhancing Cancer Research Act aims to increase diversity in oncology clinical trials

Read Now
4 min. read
Read more
 
Blog

Q&A – The New Urgency of Clinical Trials: How Oncology Leads the Evolution

September 28, 2020

In Advarra’s recent virtual symposium, experts from industry and academia met to discuss how oncology research has influenced agility in clinical trial design, particularly during the COVID-19 pandemic. Panelists talked ...

How has the COVID-19 pandemic changed oncology research--and research in general? Read more for the follow-up blog to our recent symposium:

Read Now
5 min. read
Read more
 
Blog

How Oncology Research Is Advancing Better Research

August 26, 2020

The COVID-19 pandemic has challenged every aspect of the clinical research industry. This new urgency has affirmed certain clinical trial innovations originally pioneered in the oncology space.

Innovations in oncology have sparked advancements in the clinical trial industry and empowered COVID-19 research. Read more:

Read Now
3 min. read
Read more

Visit the Resource Library

Ready to make your research safer, smarter, faster?

Contact Us